Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca sees fall in 2016 earnings as Crestor loss weighs

Published 02/04/2016, 03:33 AM
Updated 02/04/2016, 03:33 AM
© Reuters. The logo of AstraZeneca is seen on a medication package in a pharmacy in London

© Reuters. The logo of AstraZeneca is seen on a medication package in a pharmacy in London

By Ben Hirschler

LONDON (Reuters) - Drugmaker AstraZeneca (L:AZN) warned on Thursday that revenue and earnings would drop this year due to the arrival of cheap generic rivals to its cholesterol fighter Crestor, which will offset growth in sales of newer medicines.

The company, which saw off a takeover attempt by Pfizer (N:PFE) in 2014, is expected to see a trough in profits in this year and next before a hoped-for resurgence on the back of a promising pipeline of experimental drugs.

For the current year, AstraZeneca said that would mean a low to mid single-digit percentage decline in both revenue and core earnings per share, which exclude certain items, at constant exchange rates.

With currencies expected to have a further adverse impact of around 3 percent, the downbeat outlook dragged the shares down more than 3 percent in early trading.

Chief Executive Pascal Soriot said AstraZeneca faced a "transitional period" due to the expiry of the U.S. patent for Crestor in May 2016, but the company was poised for a comeback.

"We're confident that our strong execution on strategy, combined with the benefits of focused investments and new launches, keeps us on track to return to sustainable growth in line with our targets," he said.

Revenue in the fourth quarter of last year fell 5 percent to $6.4 billion, hit by earlier drug patent expiries, generating core earnings per share of 94 cents, up 26 percent.

Industry analysts had on average forecast quarterly sales of $6.29 billion and earnings of 95 cents a share, according to Thomson Reuters.

In addition to the Crestor hit, 2016 results will also be suppressed by short-term profit dilution caused by the recent acquisitions of Acerta Pharma and ZS Pharma.

"AstraZeneca's results demonstrate progress is being made, with a number of positives clearly visible," said Mick Cooper of equity research house Trinity Delta. "However, the overwhelming feeling remains that the light at the end of the tunnel is still some way away."

Soriot has been active in making bolt-on acquisitions of promising biotech companies to complement in-house research, while at the same time divesting non-core products to help pay the bills.

Such divestments, or "externalisation" deals, contributed $1.1 billion to 2015 revenue and that figure is expected to be higher in 2016, the company said.

AstraZeneca has bet heavily on cancer medicine as a driver of future growth and it has several promising new products, including recently launched lung cancer pill Tagrisso.

© Reuters. The logo of AstraZeneca is seen on a medication package in a pharmacy in London

It also has high hopes in the hot cancer area of immuno-oncology but here it is competing with several tough rivals, including Bristol-Myers Squibb (N:BMY), whose injectable drug Opdivo has a established a particularly strong position.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.